MHRA-101352-PIP01-24-M01 (update)

Key Facts

PIPS Key Facts
Active Substance
Active Substance:
  • Autologous tumour-infiltrating lymphocytes (LN-144/LN-145)
Invented Name
PIP Number MHRA-101352-PIP01-24-M01 (update)
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Dispersion of infusion
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
Conditions / Indications:
  • Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)
Route(s) of administration
Route(s) of administration:
  • Intravenous use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
Compliance Check Decision Date
Compliance Check Procedure Number
Compliance procedure number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Autologous tumour-infiltrating lymphocytes (LN-144/LN-145).pdf
Published Date 24/06/2024